Trial Profile
A study to evaluate the differential effects of fingolimod and copaxone upon FoxP3+ regulatory B-cells in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 23 Dec 2015 New trial record